Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

KUEMMERLE-DESCHNER, Jasmin; HACHULLA, E.; CARTWRIGHT, R.; Hawkins, P.; TRAN, T.; Bader-Meunier, B.; HOYER, J.; GATTORNO, M.; Gül, Ahmet; SMITH, J.; LESLIE, K.; JIMENEZ, S.; MORELL-DUBOIS, S.; DAVIS, N.; PATEL, N.; WIDMER, A.; PREISS, R.; Lachmann, H.

doi:10.1136/ard.2011.152728

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

KUEMMERLE-DESCHNER J. B., HACHULLA E., CARTWRIGHT R., Hawkins P. N., TRAN T. A., Bader-Meunier B., ...More

ANNALS OF THE RHEUMATIC DISEASES, vol.70, no.12, pp.2095-2102, 2011 (SCI-Expanded)

Publication Type: Article / Article
Volume: 70 Issue: 12
Publication Date: 2011
Doi Number: 10.1136/ard.2011.152728
Journal Name: ANNALS OF THE RHEUMATIC DISEASES
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.2095-2102
Istanbul University Affiliated: Yes

Abstract

Objective Longer-term effects of prolonged selective interleukin-1 beta blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date.